Corporate PresentationDownload January 2025 Presentation Select HighlightsFebruary 11, 2025Oppenheimer Healthcare Life Sciences ConferenceAccess Webcast »January 15, 2025J.P. Morgan Healthcare ConferenceView Presentation »December 7, 2023STAT6 Program Highlighted in Sanofi R&D DayAccess Webcast » Latest Press ReleasesMay 19, 2025Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma ModelRead More »May 7, 2025Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous UrticariaRead More »February 10, 2025Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceRead More »January 10, 2025Recludix Pharma to Present at the Annual J.P. Morgan Healthcare ConferenceRead More » More Press Releases Events and PresentationsMay 18, 2025Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammationView Poster »May 8, 2025Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous UrticariaView Poster »February 11, 2025Oppenheimer Healthcare Life Sciences ConferenceAccess Webcast »January 15, 2025J.P. Morgan Healthcare ConferenceView Presentation » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
